Cipla Ltd.

CIPLA

₹1569.7

0.65% (10.1)

Market Cap

₹1,26,185 Cr.

P/E

23.40

Key Ratios

Edit Ratio's

Market cap

1.26 L Cr

23.40

Prom Holding

29.19 %

ROE (%)

16.90

ROCE (%)

22.02

Div Yield (%)

1.03

Sales

27,811 Cr

OPM (%)

25.85 %

Debt to Equity

0.00

Edit Ratio's

About

Cipla is a leading pharmaceutical company that manufactures, develops, and markets a wide rang… Read more

Low

1335

52W Range

High

1702

Timeline

Key company specific updates

Company Timeline

Subscribe now for more updates

Custom financial statement

New

Edit rows

Forensics

11 Yes

Positive for this company

2 Neutral

Neutral for this company

4 No

Negative for this company

0 No Data

Insufficient data to analyse

Accounting & Shareholding

Contingent Liabilities

Company does not have significant contingent liabilities
Depreciation Effect

Depreciation accounting is not leading to increase in profits
Other Income

Other income is not affecting ratios of the company
Pledge

Promoters have not pledged a significant portion of their holding
Promoter Holding

Promoter has not sold any shares in the last 90 days
Retail Holding

Retail has been buying the stock which is usually a sign of exuberance
Revenue Recognition

Chances of aggressive revenue recognition - operating profit of company is not getting converted to cash and recievables rising faster than sales

Price & Performance

Capex vs ROCE

Roce of the company has increased over the last three years
ROE

Net profit margin is responsible for roe increase over last 10 years
Share price

Share price has increased over last 10 years due to earnings
Working Capital

Working capital of the company seems to be under control
Current vs Historic Valuation

Company is trading at a discount to 3yr historic valuations
Debt

Company should not have issues servicing its debt
ROCE Strength

Roce of the company is consistently strong
Balance Sheet Strength

Balance sheet of the company is strong. but it might have issues paying it suppliers
Sales Growth

Sales of the company has grown at a slow pace
Margin Stability

Margins of the company are volatile

Market Share

1.36 %

(as of Jul 22)

Historic

Anti - Diabetes - Market Share

7.76 %

(as of Jul 22)

Historic

Anti-Infectives - Market Share

0.96 %

(as of Nov 21)

Historic

Anti-Malarial - Market Share

5.93 %

(as of Nov 21)

Historic

Antineo Plastic - Market Share

0.79 %

(as of Nov 21)

Historic

Blood Related - Market Share

4.48 %

(as of Jul 22)

Historic

Cardiovascular - Market Share

2.19 %

(as of Nov 21)

Historic

Dermatology - Market Share

0.55 %

(as of Nov 21)

Historic

Endocrinology - Market Share

2.37 %

(as of Jul 22)

Historic

Gastro-Intestinal - Market Share

1.85 %

(as of Nov 21)

Historic

Gynecology - Market Share

2.97 %

(as of Nov 21)

Historic

Neurological - Market Share

8.92 %

(as of Nov 21)

Historic

Ophthalmology - Market Share

1.94 %

(as of Nov 21)

Historic

Pain - Market Share

5.20 %

(as of Sep 24)

Historic

Pharmaceutical Sector - Market Share

23.76 %

(as of Nov 21)

Historic

Respiratory - Market Share

4.31 %

(as of Jul 22)

Historic

Sex Stimulants - Market Share

0.07 %

(as of Oct 19)

Historic

Stomatological - Market Share

18.51 %

(as of Nov 21)

Historic

Urology - Market Share

0.06 %

(as of Jul 22)

Historic

Vaccines - Market Share

0.62 %

(as of Jul 22)

Historic

Vitamin & Dietary Supplements - Market Share

Revenue mix

Product Wise Break-Up

Therapeutic Area Wise Break-Up - Domestic

Location Wise Break-Up - Global API

Location Wise Break-Up

Therapeutic Area Break-Up - Global API

Operating Profit Break-Up

Asset Break-Up

Operational Metrics

Number of ANDA's Filed in USA (.)
Source
Number of ANDA's Approved By USFDA (.)
Source
Domestic Sales Growth - YoY (%)
Source
US DMF Filings (.)
Source
R&D as a % of Total Sales (%)
Source

Peer Comparison

Brands

Bronco cough syrup

Coryx

Corporate Actions

Consolidated

DATE

DETAILS

Show Less

Suppliers

Bharat Dynamics Ltd.
Laurus Labs Ltd.
Atul Ltd.
Aarti Industries Ltd.
Shakti Pumps (India) Ltd.
Borosil Renewables Ltd.
EPL Ltd.
Ion Exchange (India) Ltd.
GMM Pfaudler Ltd.
Aarti Drugs Ltd.
Cigniti Technologies Ltd.
IOL Chemicals And Pharmaceuticals Ltd.
Marine Electricals (India) Ltd.
Venus Pipes & Tubes Ltd.
TCI Express Ltd.
Vidhi Specialty Food Ingredients Ltd.
Control Print Ltd.
Gulshan Polyols Ltd.
Allcargo Gati Ltd.
Empire Industries Ltd.
Hitech Corporation Ltd.
A2Z Infra Engineering Ltd.
Take Solutions Ltd.
Mitsu Chem Plast Ltd.
Arshiya Ltd.
Vivimed Labs Ltd.

Showing 5 of 26

FAQs on Cipla Ltd. Business

What does Cipla do?

Cipla is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company has its wide network of manufacturing, trading and other incidental operations in India and International markets.The company offers complex products at affordable prices, serving patients with innovative respiratory drugdevice combinations, complex formulations and a wide array of capabilities across injectables, oral solids and inhalation therapies. The company strategically leverages opportunities while managing risks.

Who are the competitors of Cipla?

Cipla major competitors are Torrent Pharma, Dr. Reddy's Lab, Mankind Pharma, Zydus Lifesciences, Lupin, Alkem Laboratories, Abbott India.
Market Cap of Cipla is ₹1,25,951 Crs.
While the median market cap of its peers are ₹1,04,130 Crs.

Is Cipla financially stable compared to its competitors?

Cipla seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

View FAQ's On Shareprice

Cash Flow Machines

Actual Cash profits are more important than accounting profits. List of companies spitting out cash profits

Run Query

Global Leaders

Companies with a dominant global position in a product. Might be a sign of very strong moat.

Run Query

Company Filing

	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release	May Jul	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Investor Presentation	May Jul	Feb Mar Jun Sep Dec	Mar Jun Sep Dec	Mar May Jun Jul Sep Dec	Jan Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Conference Call	Mar Jul	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Conference Call SummaryCon Call Summary Powered by Gemini

Discussions & Analysis

Cipla Ltd.

View the discussion on ValuePickr

Pharmaceutical Sector

How The Pharma Industry Works - PPFAS

Deep Dive into Pharma Sector - Omkara Capital

Pharma Compliance In-Depth - Amit Rajan

Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar

Nutraceuticals- Industry Overview - Value Educator

GLP-1: The Drug Redefining Diabetes, Obesity, and Pharma’s Future - Perpetuity

Generic Opportunity for Indian Pharma Companies - Anish Moonka

Understanding the CDMO Sector - Will It Be The Next Megatrend - SOIC

Ideas Dashboard

Results

Timeline

Watchlist

Portfolio

Alerts

Stock Screener

Market

Raw Material

Cipla Ltd.

Cipla Ltd.

Key Ratios

About

Timeline

Company Timeline

Custom financial statement

Forensics

11 Yes

2 Neutral

4 No

0 No Data

Accounting & Shareholding

Contingent Liabilities

Depreciation Effect

Other Income

Pledge

Promoter Holding

Retail Holding

Revenue Recognition

Price & Performance

Capex vs ROCE

ROE

Share price

Working Capital

Current vs Historic Valuation

Debt

ROCE Strength

Balance Sheet Strength

Sales Growth

Margin Stability

Market Share

Revenue mix

Product Wise Break-Up

UNLOCK PREMIUM

Therapeutic Area Wise Break-Up - Domestic

UNLOCK PREMIUM

Location Wise Break-Up - Global API

UNLOCK PREMIUM

Location Wise Break-Up

UNLOCK PREMIUM

Therapeutic Area Break-Up - Global API

UNLOCK PREMIUM

Operating Profit Break-Up

UNLOCK PREMIUM

Asset Break-Up

UNLOCK PREMIUM

Operational Metrics

Peer Comparison

Brands

Corporate Actions

Suppliers

FAQs on Cipla Ltd. Business

What does Cipla do?

Who are the competitors of Cipla?

Is Cipla financially stable compared to its competitors?

Similar Companies

Company Filing

Discussions & Analysis

SIGN UP FOR FREE